SEC Comment Letter 0000000000-24-000717 to BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Jan. 19, 2024 · CIK: 0001720893 · Accession: 0000000000-24-000717
AI Filing Summary & Sentiment
File numbers found in text: 333-276488
Letter
United States securities and exchange commission logo January 19, 2024 Dr. Vimal Mehta Chief Executive Officer BioXcel Therapeutics, Inc. 555 Long Wharf Drive New Haven, CT 06511 Re:BioXcel Therapeutics, Inc. Registration Statement on Form S-3 Filed January 12, 2024 File No. 333-276488 Dear Dr. Vimal Mehta: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Keith Halverstam, Esq.
Show Raw Text
United States securities and exchange commission logo
January 19, 2024
Dr. Vimal Mehta
Chief Executive Officer
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
Re:BioXcel Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 12, 2024
File No. 333-276488
Dear Dr. Vimal Mehta:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Keith Halverstam, Esq.